Isabel Pimentel, MD

Proud to lead this paper inspired by Common Sense Oncology movement @csoncol A collective reflection on #Oncology , moving beyond purely biologicistic and pharmacological models Co-authored by 20+ oncology professionals from 17 hospitals in 🇪🇸 and 🇮🇹 doi.org/10.3332/ecance…

@dr_yakupergun Probably would add ICI to the antracycline-taxane regimen for BC (data on ICI pCR benefit on G3 ER positive BCs as they are usually basal like subtype). No data on olaparib benefit in thos setting. Consider add 5FU and give FEC instead of AC, but not CAPOX.

Case discussion 43-year-old premenopausal woman with synchronous colon and breast cancer. Colon: right-sided, T3N1, MSI-H. Breast: right mastectomy + SLNB. Two foci: node negative – 4.8 cm, luminal A–like – 1.8 cm, grade 3, Ki-67 40%, Oncotype DX: score 37 gPALB2 mutation present How would you design the adjuvant treatment strategy for this patient? @OncBrothers @SuyogCancer @PTarantinoMD @Dr_RShatsky @BijoyTelivala @ErikaHamilton9 @stolaney1 @RenoHemonc @UmutDisel @BianchiniGP @JAMouabbi @kazuki_nozawa @Onco_Cifu88 @benjiwal

“This trial supports the value of a functional RAD51-based HRD assessment to refine patient selection for PARP inhibitors,” said Isabel Pimentel, MD, on breast cancer therapy. Read more here: hubs.li/Q03YV7Tj0 #SABCS25 #bcsm #Oncology | @Dr_IPimentel

Inspiring and insightful talk by Abigail Johnston 🙌 @SABCS2025

400mg of Ribociclib at 1st line mBC failed to demonstrate non-inferiority in ORR, but same PFS and lower QTc prolongation and neutropenia. Quite a large patient population could benefit of this dose reduction

The #Human #Crisis of #Cancer demands more than research, It demands revolutionary action and #implementation ​The recently launched @TheLancetOncol #Commission delivers the evidence & strategy. We lead with data, we fight for lives 4 an accountable human #dignity in #care 👇

@dr_yakupergun @Nature Agree! But this opens a Pandora’s box… The same happens with investigators presenting pivotal trial results at international meetings who havent actually seen the patients.”

It’s striking that most editorial boards of @Nature and its affiliated journals (Medicine, Cancer, Communications, Reviews, etc.) include almost no editors with clinical backgrounds, despite publishing studies with major clinical implications. The “PhD-only” editorial model may ensure methodological rigor, but it often fails to recognize the true clinical relevance of findings. Scientific novelty alone does not equal patient benefit. In my view, this system is fundamentally flawed. Journals that shape clinical practice should include editors with real patient-care experience to properly evaluate translational and therapeutic significance. Someone who has never interacted with patients should not have the authority to judge or reject research that affects patient care. Desk rejections made solely by non-clinical editors—without input from expert reviewers—undermine the credibility of clinical publishing.

How much data do oncologists need to acknowledge cross-resistance between ADCs with the same payload? It’s like sequencing capecitabine after 5-FU or paclitaxel after docetaxel — just a much higher cost and no QoL gain.

@oncologician @OncBrothers @DrRishabhOnco @stolaney1 @PTarantinoMD @matteolambe @dr_yakupergun @UmutDisel @LoiSher @hoperugo @ndenduluri1 You haven't said clinical stage or TILs. But w/pCR neither option, much less with complications asociated with a regimen that is less toxic than AC...

F/56 yrs ,Early TNBC Pacli carbo x 12# weekly horrendous complications to chemo MRM - pCR Brca + WWYD 1) ddAC x 4 2) PARPi @OncBrothers @DrRishabhOnco @stolaney1 @PTarantinoMD @matteolambe @dr_yakupergun @UmutDisel @LoiSher @hoperugo @ndenduluri1

@Dr_RShatsky @OncBrothers @stolaney1 @PTarantinoMD @ErikaHamilton9 @SPremji7866 @sdent_cardioonc @dr_yakupergun @BijoyTelivala Same here!

@OncBrothers @stolaney1 @PTarantinoMD @ErikaHamilton9 @SPremji7866 @sdent_cardioonc @dr_yakupergun @BijoyTelivala I do weekly carbo/taxol q3 week pembro_> ddAC/ q3 week pembro

When using KN522 in NeoAdj settings for TNBC, what’s your preferred sequence for chemo in majority of your pts? @stolaney1 @PTarantinoMD @ErikaHamilton9 @SPremji7866 @sdent_cardioonc @dr_yakupergun @BijoyTelivala @Dr_RShatsky #bcsm

@ozdogan_md Chemo free ADCs? Never saw one!

Paradigm Shift in 1L TNBC We may be witnessing the end of chemotherapy’s monopoly in PD-L1–negative metastatic TNBC. Dato-DXd delivers the first OS benefit in this setting. SG shows a robust PFS advantage and prolonged DOR ≈ 12 mo. Next frontier → sequencing & chemo-free ADC + IO regimens. #ESMO25 #BreastCancer #ADC #TNBC #DatopotamabDeruxtecan #SacituzumabGovitecan #Oncology @myESMO @OncLive @CParkMD @tugbawitter @Dr_ElvinaA @atakansare2016 @drmukremin @dr_yakupergun @OncoAlert @alimurattat

@PTarantinoMD HER2DX assessment

@PTarantinoMD This is sad. What about THP x 4 cycles followed by MRI assessment in complete clinical response? +/- HER2 assessment.

A lot of heterogeneity in the management of stage II HER2+ breast cancer. The only consensus -> no anthracyclines!

As #ESMO25 comes to an end, I received a private message from a patient advocate — expressing concern that talks highlighting patient-reported outcomes and methodological transparency were scheduled after major drug-focused trials. She also noted that in many industry-sponsored studies, patient-reported outcomes almost always appear in favor of the drug, while real-life patient experiences often remain underrepresented. This reminds us that the patient voice and methodological integrity must remain central in scientific discussions. If our ultimate goal is to serve patients, then we must listen to patients and their advocates.

Great work!

An Outstanding @rillepihlak presenting her study on the #humancrisis in oncology, as part of the background work for the @TheLancetOncol Commission! Too Less education 🎓 Too high educational need 👨‍🏫 An inexcusable gap !! #ESMO25 #ESMOAmbassadors

💥Great discussion by Dr. Garrido-Castro @danafarber on 1st line TROP2 ADCs in mTNBC >>Interpreting OS in the absence of crossover >>Balancing efficacy with toxicity and QOL ⚠️limited global access to ADCs #ESMO2025

ddAC-T + low dose pembro (1/10th standard dose) improves pCR among extremely high risk group of TNBC (> 80% node +) 🌟 13.3% improvement in pCR 🤯 ~ 10% hypothyroidism RDI, delayed and completion of tx all 🟰 #ESMO25 #ESMOAmbassadors

@ivanpantic1980 🤣🤣🤣

Por ejemplo, qué habrá detrás de estas señales de prohibido... Ya despierta más interés en mi que todos los simposios satélite

Iba a escribir algo superinspiring de estar en #ESMO25 pero acabo de ser absorbido por un espacio liminal backroomero en el palacio de congresos de Berlin.

BIG ANNOUNCEMENT📣: I haven’t been this excited to be part of something new in 15 years… Thrilled to reveal the passion project I’ve been working on for the past year and a half!🙀🥳 It started from my frustration with the depressing effect that the current publishing system has on the well-being of myself, my team, and pretty much every scientist I know (maybe you’ve noticed from my stupid jokes… :) I was exhausted of dealing with the huge delays, reviewers that can be abusive, and how arbitrary it all is. Unfortunately, the most important factors are often WHO your reviewers are and who YOU are... It’s clear we need alternatives or at least ways to improve the situation. So, together with a really special and talented team we worked to develop this idea into “qed” a platform where you can get CONSTRUCTIVE feedback on your own work or CRITICALLY assess other people’s papers. It can be a real difference maker if many of you join us (thousands have tried it already, but today we release a NEW and much stronger version ;) Let’s harness qed to put the power back in the scientists’ hands, to do, to read & to publish science on our own terms. I’m dying for you to TRY IT, and it’s very simple - just drop a paper (the link to the website is in the replies👇) - it’s completely secure, private, and free, and you get results fast. Please show your support, SHARE, tell your friends, and let’s be the revolution 🫵!